Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Phillip Habib

Advanced Heart Failure and Transplant Cardiology Delray Beach, FL Medical Doctor

NPI 1326262874 CMS profile 242167

5035 Via Delray, Delray Beach, FL 33484

Open in the dashboard

General payments

$305,371

439 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$34,681 paid to institutions, not to them · program years 2020–2021

Through program year 2025, Phillip Habib of Delray Beach, FL is reported in the CMS Open Payments database as having received $305,371 across 439 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $34,681 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40,974 34
2024 General $45,960 40
2023 General $56,852 50
2022 General $33,020 30
2021 General $31,409 62
2020 General $23,632 84
2019 General $73,524 139

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Phillip Habib
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Phillip Habib were reported at $40,974. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Phillip Habib Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $73,524 $863 $224–$4,562 $163
2020 $23,632 $452 $122–$3,992 $114
2021 $31,409 $550 $159–$3,571 $132
2022 $33,020 $729 $221–$4,357 $149
2023 $56,852 $1,002 $309–$5,827 $160
2024 $45,960 $931 $273–$5,204 $164
2025 $40,974 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $89,207 69 payments
  2. AstraZeneca Pharmaceuticals LP $62,558 57 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $39,537 32 payments
  4. Novartis Pharmaceuticals Corporation $38,725 48 payments
  5. Actelion Pharmaceuticals US, Inc. $35,059 86 payments
  6. Pfizer Inc. $25,976 23 payments
  7. Lilly USA, LLC $9,062 11 payments
  8. Abbott Laboratories $1,351 15 payments
  9. Abiomed $1,091 12 payments
  10. United Therapeutics Corporation $486 24 payments
  11. Other $2,318 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $269,026 126 payments
  2. Food and Beverage $16,607 285 payments
  3. Consulting Fee $9,936 6 payments
  4. Travel and Lodging $9,708 16 payments
  5. Education $93 6 payments
Products named General payments · program years 2019–2025
  1. CAMZYOS $86,734 62 payments
  2. FARXIGA $52,894 47 payments
  3. ENTRESTO $36,023 46 payments
  4. VYNDAQEL $25,976 23 payments
  5. JARDIANCE Diabetes $19,876 14 payments
  6. JARDIANCE Diabetes $19,627 17 payments
  7. WAINUA $9,552 8 payments
  8. UPTRAVI $9,246 49 payments
  9. JARDIANCE Diabetes $8,802 10 payments
  10. OPSUMIT $8,767 10 payments
  11. Other $16,146 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,735

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$4,915,658

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

42.3%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 76 $2,271,208
Camzyos Mavacamten Brand 80 $661,722
Opsumit Macitentan Brand 50 $618,550
Uptravi Selexipag Brand 28 $583,070
Eliquis Apixaban Brand 173 $194,771
Adempas Riociguat Brand 12 $169,590
Entresto Sacubitril/Valsartan Brand 105 $143,792
Jardiance Empagliflozin Brand 77 $91,256
Farxiga Dapagliflozin Propanediol Brand 61 $78,689
Tadalafil Generic 17 $25,077

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$215,598

Medicare's payments for the services billed

Medicare patients

997

Average age 81

Services billed

2,844

501 women, 496 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Arthritis 63%
Atrial fibrillation 54%
Chronic kidney disease 52%
Heart failure 50%
Diabetes 44%
Depression 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $31,449
$31,449 80 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $8,895
  • Lilly USA, LLC $780
$9,675 77 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $2,270
$2,270 61 —
WAINUA
  • AstraZeneca Pharmaceuticals LP $2,150
$2,150 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

439 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record